Agios Pharmaceuticals Inc. (NASDAQ:AGIO) Director Lewis Clayton Jr. Cantley sold 627 shares of the firm’s stock in a transaction dated Monday, July 25th. The stock was sold at an average price of $41.85, for a total transaction of $26,239.95. Following the sale, the director now owns 112,167 shares of the company’s stock, valued at approximately $4,694,188.95. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Lewis Clayton Jr. Cantley also recently made the following trade(s):
- On Tuesday, July 26th, Lewis Clayton Jr. Cantley sold 2,504 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $42.80, for a total transaction of $107,171.20.
Shares of Agios Pharmaceuticals Inc. (NASDAQ:AGIO) traded up 3.71% during midday trading on Wednesday, hitting $45.56. 473,416 shares of the company traded hands. Agios Pharmaceuticals Inc. has a 52 week low of $33.50 and a 52 week high of $115.39. The stock’s market capitalization is $1.73 billion. The stock has a 50 day moving average of $45.45 and a 200-day moving average of $45.24.
A number of equities analysts recently commented on the stock. Canaccord Genuity raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price target for the stock from $50.00 to $90.00 in a research report on Monday, June 13th. Cowen and Company reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, May 18th. Vetr raised shares of Agios Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $68.42 price target on the stock in a research report on Monday, June 13th. JPMorgan Chase & Co. raised shares of Agios Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $50.00 to $62.00 in a research report on Monday, June 13th. Finally, Credit Suisse Group AG raised their price target on shares of Agios Pharmaceuticals from $65.00 to $70.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 18th. Six equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $63.44.
An institutional investor recently raised its position in Agios Pharmaceuticals stock. State Board of Administration of Florida Retirement System raised its stake in shares of Agios Pharmaceuticals Inc. (NASDAQ:AGIO) by 7.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 22,672 shares of the biopharmaceutical company’s stock after buying an additional 1,624 shares during the period. State Board of Administration of Florida Retirement System owned approximately 0.06% of Agios Pharmaceuticals worth $1,472,000 at the end of the most recent reporting period.
Agios Pharmaceuticals, Inc (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells.
